<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-19.anc" start="12137" end="12142" sStart="12089" offset="48" sid="r7.1.use.v.0070" wn="1" wnkey="use%2:34:01::" annotator="veweser" text="PGE 2 concentrations were determined using a commercially available ELISA assay (Cayman Chemical Company, Ann Arbor, MI)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-19.anc" start="28101" end="28107" sStart="null" offset="0" sid="null" wn="1" wnkey="try%2:41:00::" annotator="comcgeetubb" text="Pursuing future research into the combinatorial chemopreventive/chemotherapeutic potential of aspirin may be of greater value than &lt;b&gt;trying&lt;/b&gt; to account for the discordant effect." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-19.anc" start="9901" end="9913" sStart="null" offset="0" sid="null" wn="3" wnkey="transfer%2:38:05::" annotator="tofox" text="The labelling reaction was terminated by &lt;b&gt;transferring&lt;/b&gt; the slides to 50 mL of stop buffer (10 mM EDTA, pH 8.0) for 5 minutes." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-19.anc" start="29464" end="29468" sStart="null" offset="0" sid="null" wn="1" wnkey="read%2:31:00::" annotator="veweser" text="All authors &lt;b&gt;read&lt;/b&gt; and approved the final manuscript." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-19.anc" start="29464" end="29468" sStart="null" offset="0" sid="null" wn="1" wnkey="read%2:31:00::" annotator="tofox" text="All authors &lt;b&gt;read&lt;/b&gt; and approved the final manuscript." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-19.anc" start="29464" end="29468" sStart="null" offset="0" sid="null" wn="1" wnkey="read%2:31:00::" annotator="comcgeetubb" text="All authors &lt;b&gt;read&lt;/b&gt; and approved the final manuscript." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-19.anc" start="29464" end="29468" sStart="null" offset="0" sid="null" wn="1" wnkey="read%2:31:00::" annotator="cgozo" text="All authors &lt;b&gt;read&lt;/b&gt; and approved the final manuscript." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-19.anc" start="29464" end="29468" sStart="null" offset="0" sid="null" wn="1" wnkey="read%2:31:00::" annotator="brubin" text="All authors &lt;b&gt;read&lt;/b&gt; and approved the final manuscript." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-19.anc" start="19490" end="19500" sStart="null" offset="468" sid="r10.particular.j.0312" wn="2147483645" wnkey="null" annotator="brubin" text="To date no studies or case reports have examined the use of aspirin in the treatment of FAP, although various clinical trials are under way [ 33 ] . In accordance with the above data, studies conducted in animals have always employed a prevention strategy as well [ 4 7 9 ] . To our knowledge, this is the first study to examine the therapeutic potential of aspirin in a rodent model of colon carcinogenesis, in particular, the Min /+ murine model of polyposis." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-19.anc" start="23184" end="23190" sStart="null" offset="177" sid="r8.number.n.0212" wn="1" wnkey="number%1:07:00::" annotator="cgozo" text="Finally, R -flurbiprofen (10 mg/kg/day) orally administered to Min /+ for 42 days starting at 10 weeks of age was also able to decrease tumour number by greater than 58% [ 11 ] ." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-19.anc" start="15771" end="15775" sStart="null" offset="15" sid="r8.life.n.0489" wn="2147483647" wnkey="null" annotator="veweser" text="The quality of life of the Min /+ mice, as assessed by change in body weight, hematocrit level and overall survival, was not altered in the aspirin-treated group compared to the vehicle-treated group (table 2)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-19.anc" start="16736" end="16742" sStart="null" offset="111" sid="r9.level.n.0613" wn="1" wnkey="level%1:07:00::" annotator="veweser" text="Anaemia is characteristic of the model [ 29 ] . Both treatment groups displayed hematocrit levels 25-30% lower than expected values." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-19.anc" start="15121" end="15127" sStart="null" offset="17" sid="r9.level.n.0690" wn="1" wnkey="level%1:07:00::" annotator="anfahmy" text="PGE 2 levels (3." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-19.anc" start="7593" end="7599" sStart="null" offset="0" sid="null" wn="3" wnkey="image%1:06:00::" annotator="brubin" text="&lt;b&gt;Images&lt;/b&gt; were captured and analysed by use of computerised software (Scion &lt;b&gt;Image&lt;/b&gt;, Scion Corporation, Frederick, MD)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-19.anc" start="3611" end="3615" sStart="null" offset="273" sid="r9.full.j.0563" wn="3" wnkey="full%5:00:00:complete:00" annotator="cgozo" text="Polyps (multiple) are generally localized to the small intestine in Min /+ mice, opposed to the colons of FAP suffers [ 27 ] . In Min /+ mice adenoma formation is thought to occur within the first few weeks of life, with a full compliment of adenomas being attained by approximately 9 weeks of age (60-67 days of age) [ 6 28 ] . Following this time, adenoma multiplicity is thought not to change, however, adenoma size may still increase [ 6 28 ] . Min /+ mice are also normally found to develop anaemia by 60 days of age and possess a shortened life span of roughly 120 days (17 weeks) [ 29 ] ." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-19.anc" start="24574" end="24578" sStart="null" offset="172" sid="r9.fold.v.0433" wn="2147483645" wnkey="null" annotator="veweser" text="The treatment regime employed was sufficient to attenuate COX activity by 75% and increased the number of apoptotic bodies within tumours by greater than 2-fold." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-19.anc" start="14736" end="14740" sStart="null" offset="53" sid="r9.fold.v.0349" wn="2147483645" wnkey="null" annotator="veweser" text="Vehicle-treated Min /+ mice displayed a 2-fold increase in their capacity to generate PGE 2 when compared to wild type mice (figure 2)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-19.anc" start="24853" end="24857" sStart="null" offset="136" sid="r9.fold.v.0918" wn="" wnkey="null" annotator="anfahmy" text="These authors demonstrated a &gt;50% reduction in small intestinal tumour number and PGE 2 content and a &gt;4-fold increase in apoptosis." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-19.anc" start="22094" end="22103" sStart="null" offset="709" sid="r8.1.different.j.0709" wn="4" wnkey="different%5:00:01:other:00" annotator="veweser" text="[ 9 ] , but employed far greater doses of aspirin (45 and 90 mg/kg/day) and reported no dose-response relationship and a maximal suppression of 55% [ 7 ] . Furthermore, in the rat model of azoxymethane-induced colon carcinogenesis, aspirin has also only been found to inhibit aberrant crypt foci and tumour development by no more than 65% [ 4 39 ] . Coincidentally, epidemiological data also report reductions in the 40-50% range [ 13 14 15 32 ] . However, whether this can be used as an argument to support the notion that aspirin is only able to suppress tumour formation by 50% is difficult to extrapolate because two different end points are being examined (i.e." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-19.anc" start="27632" end="27636" sStart="null" offset="28" sid="r11.able.j.0893" wn="1" wnkey="able%3:00:00::" annotator="anfahmy" text="The combination therapy was able to completely abolish all macroscopically visible tumours in 47% of the animals treated [ 47 ] . This could prove to be very advantageous since it may allow for lower doses of NSAIDs to be used, thereby limiting the adverse effects associated with long term NSAID use." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-19.anc" start="4466" end="4470" sStart="null" offset="55" sid="r11.able.j.0572" wn="1" wnkey="able%3:00:00::" annotator="anfahmy" text="We therefore wanted to determine if aspirin is able to reduce the number and size of adenomas in Min /+ mice with established polyposis." />
  </sentences>
</list>